Scinai Immunotherapeutics Restructures Debt, Boosts Equity
Company Announcements

Scinai Immunotherapeutics Restructures Debt, Boosts Equity

Scinai Immunotherapeutics (SCNI) has released an update.

Scinai Immunotherapeutics has successfully restructured its loan with the European Investment Bank, converting approximately $29 million of debt into preferred equity and reducing its debt balance to $273,000. This financial maneuver has elevated the company’s stockholders’ equity above the Nasdaq’s minimum requirement of $2.5 million, potentially bringing it back into compliance with listing standards. The preferred shares issued in the deal have specific terms, including a 12-month lock-up period and conversion restrictions to maintain the company’s investment profile.

For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics to Hold Annual Shareholder Meeting
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics Licenses Global Rights
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics Restructures Debt, Eyes Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App